Encad-Biolic solution for injection 3.5% ampoule 3 ml No. 10

Pharmacological properties

Encad is a mixture of products of enzymatic hydrolysis of yeast RNA (pyrimidine nucleoside-3-phosphates and oligoribonucleotides with a terminal 3-phosphate). Encad regulates the exchange of nucleotides in tissues, has immunomodulatory properties, improves membrane function, muscle bioenergetics, impulse conduction along motor nerves, and reduces the severity of myodystrophic processes.

Indication

Hereditary tapetoretinal abiotrophies, Sjögren's disease, degenerative diseases of the neuromuscular system, hereditary forms of myopathies (early stages), congenital and acquired myopathic syndrome, various forms of neural amyotrophies, consequences of neuroinfections, spinal amyotrophies.

Application

Intramuscularly, subconjunctivally, by phonophoresis or topically.

Before using the drug, it is necessary to conduct an intradermal test. For this purpose, Enkad in a dose of 0.1 ml of 3.5% solution is injected under the skin into the inner surface of the forearm. The test is considered positive if a papule with a diameter of 1 cm appears 1 day after the drug is administered. Treatment is started only with a negative test.

In / m Enkad is used in adults with tapetoretinal abiotrophies daily: 5-6 ml of 3.5% solution (175-210 mg/day) for 15 days. Children under 7 years old - 10 mg/day for 1 year of life; over 7 years old - 3 ml of 3.5% solution (105 mg). The daily dose is divided into 2 injections with an interval of 5-6 hours. The course of treatment is 15 days. The courses are repeated with an interval of 6, 8, 10 months, but not less than 1 time per year.

The drug can be administered simultaneously subconjunctivally at a dose of 10.5 mg per day (0.3 ml of a 3.5% solution) for 10-15 days.

In degenerative diseases of the nervous system and muscles, Encad is prescribed 2-3 ml of 3.5% solution (at a dose of 70-105 mg) daily or every other day for 12-15 days. The maximum single dose is 5 ml of 3.5% solution (175 mg). The course of treatment is carried out 2 times a year.

The drug is administered by phonophoresis using baths (0.5% Enkad solution). Ultrasound intensity - 0.2 W / cm 2, frequency - 880 kHz, generation mode - continuous. Duration of the procedure - 5 min. To prepare a 0.5% solution of the drug, the contents of the ampoule (3 ml) are diluted in 18 ml of sterile isotonic sodium chloride solution. The course of treatment is 10-12 daily procedures, carried out 2 times a year.

In Sjögren's disease, Enkad is recommended to be applied topically in the form of applications of 5 ml of 1% solution (50 mg) for 20 minutes on the oral mucosa. To obtain a 1% solution, the original 3.5% Enkad solution is diluted 3.5 times with isotonic sodium chloride solution. Applications are carried out 3 times a day after meals. The course of treatment is 14 days. During the year, 3-4 courses of treatment are carried out.

Contraindication

Acute inflammatory processes and diseases of viral etiology, neoplasms, cardiovascular diseases with decompensation of heart function, impaired kidney and liver function, nephrolithiasis, allergic diseases in the acute stage, pregnancy and breastfeeding, advanced and senile age. The use of Enkad by phonophoresis is also contraindicated in ocular hypotension, retinal detachment and other diseases when ultrasound treatment is contraindicated.

Side effects

With subconjunctival administration of Enkad, swelling and hyperemia of the conjunctiva may develop, which are eliminated by instillation of corticosteroids. Enlargement and tenderness of the parotid and cervical lymph nodes are also possible. In this case, further treatment with the drug should be carried out against the background of the use of antihistamines. With intramuscular administration of Enkad, chills, fever, joint pain and other allergic reactions are possible. In this case, the drug is canceled and desensitizing therapy is carried out.

Storage conditions

At a temperature of 4-10 °C, the prepared solution for phonophoresis is stored for no more than 10 days.